A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2017-09-17Actual
Enrollment · participants108Actual
Source updated2025-09-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.